Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884889 | 0.83 | CNR1 (0.41) | CNR2CNR1ALOX5 | |
| SCHEMBL25968340 | 0.78 | CNR2 (0.55) | CNR2CNR1ACHE | |
| SCHEMBL14025162 | 0.76 | CNR2 (0.68) | CNR2CNR1 | |
| SCHEMBL3537531 | 0.76 | CNR1 (0.44) | CNR2CNR1MTNR1B | |
| SCHEMBL5646550 | 0.76 | CNR2 (0.60) | CNR2CNR1ACHE | |
| SCHEMBL4881858 | 0.76 | CES2 (0.53) | BCHEACHE | |
| SCHEMBL15995315 | 0.74 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL9816389 | 0.74 | ALDH1A1 (0.39) | CNR2CNR1 | |
| SCHEMBL4888766 | 0.73 | CNR1 (0.46) | CNR2CNR1 | |
| SCHEMBL5644608 | 0.73 | CNR1 (0.52) | CNR2CNR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1853538-A2 | MODULATOR | UCL Biomedica plc (GB) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006067450-A2 | MODULATOR | UCL BIOMEDICA PLC (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262011-A1 | Modulator | CHRNA10, CNR1, CHRNA9 | CNR2 12/4885CNR1 2/4885BCHE 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.